Nordic DX

Main Menu

  • Home
  • Medical devices
  • Medical products
  • Medicine importation
  • Medicine quality

Nordic DX

Header Banner

Nordic DX

  • Home
  • Medical devices
  • Medical products
  • Medicine importation
  • Medicine quality
Medical products
Home›Medical products›Utah Medical Products, Inc. Declares Quarterly Dividend of $0.29 (NASDAQ: UTMD)

Utah Medical Products, Inc. Declares Quarterly Dividend of $0.29 (NASDAQ: UTMD)

By Joseph M. Juarez
May 11, 2022
0
0

Utah Medical Products, Inc. (NASDAQ:UTMD – Get Rating) declared a quarterly dividend on Tuesday, May 10, Zacks reports. Shareholders of record on Friday, June 17 will receive a dividend of 0.29 per share from the medical device supplier on Wednesday, July 6. This represents a dividend of $1.16 on an annualized basis and a yield of 1.37%. The ex-dividend date is Thursday, June 16.

Utah Medical Products has increased its dividend payout by an average of 38.1% per year over the past three years and has increased its dividend each year for the past 1 consecutive years.

NASDAQ UTMD traded down $0.06 during Wednesday’s trading, hitting $84.66. The stock had a trading volume of 9 shares, compared to an average volume of 13,666 shares. The company’s 50-day moving average is $87.58. The company has a market capitalization of $309.43 million, a P/E ratio of 20.24 and a beta of 0.25. Utah Medical Products has a 12-month low of $81.01 and a 12-month high of $133.87.

Separately, StockNews.com began covering Utah Medical Products in a research report on Thursday, March 31. They issued a “Strong Buy” rating on the stock.

A number of large investors have recently increased or reduced their stakes in UTMD. JPMorgan Chase & Co. increased its stake in Utah Medical Products shares by 16.9% in the first quarter. JPMorgan Chase & Co. now owns 101,769 shares of the medical device supplier worth $9,145,000 after buying 14,693 additional shares in the last quarter. Barclays PLC increased its holdings of Utah Medical Products shares by 196.3% in the fourth quarter. Barclays PLC now owns 4,157 shares of the medical device supplier worth $415,000 after buying an additional 2,754 shares in the last quarter. BlackRock Inc. increased its holdings of Utah Medical Products shares by 0.3% in the fourth quarter. BlackRock Inc. now owns 217,007 shares of the medical device supplier worth $21,700,000 after purchasing an additional 748 shares in the last quarter. Citadel Advisors LLC purchased a new stake in Utah Medical Products stock in Q4 for approximately $233,000. Finally, State Street Corp increased its stake in Utah Medical Products shares by 2.4% in the 4th quarter. State Street Corp now owns 68,934 shares of the medical device supplier worth $6,893,000 after buying an additional 1,599 shares in the last quarter. 71.44% of the shares are currently held by institutional investors.

About Utah Medical Products (Get an assessment)

Utah Medical Products, Inc. develops, manufactures and distributes medical devices for the healthcare industry. The Company offers fetal monitoring accessories, vacuum assisted delivery systems and other labor and delivery tools; Respiratory hoods for newborns DISPOSA-HOOD; and DELTRAN PLUS blood pressure monitoring systems.

Read more

Dividend history for Utah Medical Products (NASDAQ:UTMD)



Receive daily news and reviews for Utah medical products – Enter your email address below to receive a concise daily summary of breaking news and analyst ratings for Utah Medical Products and related companies with MarketBeat.com’s free daily email newsletter.

Categories

  • Medical devices
  • Medical products
  • Medicine importation

Recent Posts

  • India to prepare detailed guidelines and procedures for testing medical devices
  • Sri Lankan leader asks the world for help during financial crisis | Health, Medicine and Fitness
  • Global 3D Printing Medical Devices Market Movements in 2022 by Trend Analysis, Growth Status, Revenue Forecast to 2027
  • Second Sight Medical Products, Inc. (NASDAQ:EYES) Director Acquires $329,305.20 in Stock
  • Cough Medicines Market Statistical Forecast, Trade Analysis 2022 – Pfizer, GlaxoSmithKline, Sanofi, Merck, Novartis – Journal l’Action Régionale

Archives

  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • March 2021
  • February 2021
  • January 2021
  • November 2020
  • October 2020
  • May 2020
  • April 2019
  • Privacy Policy
  • Terms and Conditions